Biostax logo

Biostax(OTC) BTAX

Market Cap$15.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-100%
5 Year-100%
1 Year+100%
1 Month+100%
$0.00
+0.00%
+0.00Today
Biostax last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-25
Biostax stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-09-09
1 month+100%USD 0.002026-08-14
3 month+100%USD 0.002026-06-22
Year to date+100%USD 0.002025-12-30
1 year+100%USD 0.002025-09-22
3 year-99.8%USD 0.102023-09-26
5 year-99.99%USD 3.202021-09-24
Since inception-100%USD 5,100.002012-05-14

Biostax Financials at a Glance

Market Cap

$15.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-5.95 (Low)

Price

$0.00

Volume

110

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

BTAX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biostax

Biostax Corp. is a biopharmaceutical enterprise focused on the acquisition, advancement, and commercialization of innovative pharmaceutical and biotechnology solutions. The company is particularly known for its lead investigational drug candidate, Lodonal, aimed at managing HIV/AIDS.

Products and Services
  • Lodonal, an immune system modulator for HIV/AIDS management
  • Global Telehealth platform enhancing healthcare accessibility
  • JKB-122, a small molecule for autoimmune diseases
Growth Outlook
  • Recent corporate name change reflects strategic repositioning
  • Development of innovative Medtech initiatives leveraging blockchain technology
  • Focus on expanding drug portfolio to address various health conditions
Financial Highlights
  • Q3 2024 net income of -$36,197 indicates ongoing investment in R&D
  • Trailing twelve months show a consistent increase in operating expenses
  • Current liabilities exceed total assets, highlighting financial challenges
Biostax Corp. operates in a dynamic biotechnology sector, with a commitment to developing solutions for critical health issues. The company's focus on innovative drug candidates and technology platforms positions it for potential growth in the evolving healthcare landscape. Despite facing financial challenges, the ongoing investment in research and development underscores a commitment to long-term objectives. The strategic initiatives and product offerings may attract interest from investors looking for opportunities in the biopharmaceutical industry.
AI Generated • Sep 28, 2026

Industry

Biotechnology

CEO

Noreen M. Griffin

Headquarters

Winter Park, FL 32804, US

BTAX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

67.11%

Return on Capital

N/A

Return on Assets

-6695.90%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$15.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

78.71M

Volume

110

Avg. Volume

85.688

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$677.71K

EBITDA

-$616.04K

Operating Cash Flow

-$33.31K

Capital Expenditure

$0.00

Free Cash Flow

-$33.31K

Cash & ST Invst.

$0.00

Total Debt

$1.16M

Biostax Performance Analysis

Biostax annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
Biostax sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-03-31N/A
Q22024-06-30N/A
Q32024-09-30N/A
Biostax annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD 0.38N/A
20222022-12-31USD -0.10N/A
20232023-12-31USD -0.03-70.9%
Biostax sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-03-31N/A
Q22024-06-30-138.1%
Q32024-09-3095.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$15.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.93K

N/A

Employees

4

N/A

Net Income

-$36.20K

N/A

EBITDA

$16.21K

N/A

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$0.00

N/A

Total Debt

$1.16M

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.16M

N/A

Return on Assets

-66.96%

N/A

Return on Invested Capital

32.80%

N/A

Free Cash Flow

-$33.31K

N/A

Operating Cash Flow

-$33.31K

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NBIONascent Biotech, Inc.
$0.00+0.00%
BIXTBioxytran, Inc.
$0.02+5.75%
OTLCOncotelic Therapeutics, Inc.
$0.02-1.41%
CLRBCellectar Biosciences, Inc.
$1.80-3.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
NKENike
$33.16-5.66%
NVDANvidia
$235.26+1.90%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$29.27-7.84%
SPCXSpace Exploration Technologies
$158.01+6.71%

Questions About BTAX

What is the current price of Biostax?

Biostax is trading at $0.00 per share.

What is the 52-week range for Biostax?

Over the past 52 weeks, Biostax has traded between $0.00 and $0.00.

How much debt does Biostax have?

As of the most recent reporting period, Biostax reported total debt of $1.13M.

How much cash does Biostax have on hand?

Biostax reported $29.79K in cash and cash equivalents in its most recent financial results.

What is Biostax’s dividend yield?

Biostax does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.